<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02826642</url>
  </required_header>
  <id_info>
    <org_study_id>CIDH305X2102</org_study_id>
    <nct_id>NCT02826642</nct_id>
  </id_info>
  <brief_title>A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase I, Open Label, Multicenter, Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and potential efficacy of
      IDH305 with standard treatments for newly diagnosed IDH1R132 mutant acute myeloid leukemia
      (AML).
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date type="Anticipated">August 2016</start_date>
  <completion_date type="Anticipated">November 22, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting toxicities</measure>
    <time_frame>10 months</time_frame>
    <description>(escalation only)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with adverse events (AEs)</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve (AUC)</measure>
    <time_frame>36 months</time_frame>
    <description>To characterize the PK profile of IDH305 with SOC medications (each Arm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>36 months</time_frame>
    <description>To characterize the PK profile of IDH305 with SOC medications (each Arm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time taken to reach maximum plasma concentration (Tmax)</measure>
    <time_frame>36 months</time_frame>
    <description>To characterize the PK profile of IDH305 with SOC medications (each Arm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission rate (CRR)</measure>
    <time_frame>36 months</time_frame>
    <description>To characterize preliminary anti-tumor activity for each arm of the study. (Arm 1 and Arm 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>36 months</time_frame>
    <description>To characterize preliminary anti-tumor activity for each arm of the study. (Arm 1 and Arm 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival (EFS)</measure>
    <time_frame>36 months</time_frame>
    <description>To characterize preliminary anti-tumor activity for each arm of the study. (Arm 1 and Arm 2)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <arm_group>
    <arm_group_label>Arm 1: Medically fit for induction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IDH305 + Standard of care for patients that are medically fit for induction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 Medically unfit for induction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IDH305 + Standard of care for patients that are medically unfit for induction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDH305</intervention_name>
    <arm_group_label>Arm 1: Medically fit for induction</arm_group_label>
    <arm_group_label>Arm 2 Medically unfit for induction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -- Previously untreated AML. Patients with untreated, high or very high risk MDS (according
        to rIPSS or equivalent) are also permitted in Arm 2.

          -  Documentation of IDH1R132 mutation of tumor

          -  ECOG performance status â‰¤ 2

          -  Clinically fit for standard of care medication per protocol.

        Exclusion Criteria:

          -  Prior treatment for AML or MDS

          -  Any severe or uncontrolled medical conditions that would prevent the patient's
             participation in the clinical study due to safety concerns or compliance with clinical
             study procedures such as the presence of other clinically significant cardiac,
             respiratory, gastrointestinal, renal, hepatic or neurological disease.

          -  Acute Promyelocytic Leukemia

          -  Women who are pregnant or lactating

        Other protocol-defined Inclusion/Exclusion may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2016</study_first_submitted>
  <study_first_submitted_qc>July 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>newly diagnosed acute myeloid leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>myeloid dysplastic syndrome</keyword>
  <keyword>MDS</keyword>
  <keyword>IDH305</keyword>
  <keyword>standard of care in IDH1 mutant acute myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

